logo
Plus   Neg
Share
Email

MoSys Q1 Loss Narrows - Quick Facts

MoSys Inc.'s (MOSY) GAAP net loss for the first quarter of 2013 was $5.0 million or $0.12 per share, compared to a net loss of $7.2 million, or $0.19 per share in the first quarter of 2012.

The non-GAAP net loss for the first quarter of 2013 was $3.9 million, or $0.10 per share, which excludes amortization of intangible assets and stock-based compensation expense.

Total net revenue for the first quarter of 2013 was $1.3 million, compared to $1.4 million in the first quarter of 2012.

First quarter 2013 total revenue included licensing and other revenue of $0.2 million, consistent with the previous quarter and first quarter of 2012. First quarter 2013 royalty revenue was $1.1 million, compared with $1.4 million in the previous quarter and $1.2 million for the first quarter of 2012.

On average, 2 analysts polled by Thomson Reuters expected the company to report a loss of $0.15 per share on revenues of $1.45 million for the quarter. Analysts' estimates typically exclude special items.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT